Richard Lam, MD

Curriculum Vitae [ CV ]

A board-certified internist and oncologist, Richard Lam, MD, has been specializing full time at Prostate Oncology Specialists in the treatment of prostate cancer since 2001. He is our director of clinical research.

Dr. Lam has written numerous articles based on his research. He is an active member of the American Society of Clinical Oncology and the American Society of Hematology. Dr. Lam continues to promote prostate cancer awareness and education by giving lectures at various medical conferences and prostate support groups throughout the country. He is particularly interested in utilizing state-of-the-art therapeutics for advanced prostate cancer.

Dr. Lam received his undergraduate degree in biology, magna cum laude, at UCLA. He then went on to earn his medical degree at UCLA School of Medicine before completing his residency training in the specialty of internal medicine at UCLA Center of Health Sciences. He completed his oncology and hematology fellowship at Harbor-UCLA Medical Center.

He resides in Marina del Rey, CA.

LICENSURE

Medical Board of California – Physicians and Surgeons License 1996. A60442 
DEA BL5206190
NPI 1811925258

CERTIFICATIONS

American Board of Internal Medicine (Oncology) 2001
American Board of Internal Medicine 1997

HOSPITAL AFFILIATIONS

Marina del Rey Hospital, Marina del Rey
Saint John’s Hospital, Santa Monica

EDUCATION

Fellowship  University of California, Los Angeles, Harbor-UCLA Hospital, Internal Medicine, Division of Medical Oncology and Hematology, 1998-2001
Residency  University of California, Los Angeles – Center of Health Sciences, Internal Medicine, 1995-97
Internship University of California, Los Angeles – Center of Health Sciences, Internal Medicine, 1994-95
Medical School  University of California, Los Angeles – Doctor of Medicine, June 1994
Undergraduate  University of California – Los Angeles (UCLA) – Bachelor of Science, Biology, June 1990

Honors and Awards

Southern California Super Doctors, 2008-2017
Prostate Cancer Research Institute, Annual Meeting Best Speaker, 2006
Western AUA, Best Abstract – First Runner Up, 2003
Phi Beta Kappa, UCLA, 1990
Graduated magna cum laude, UCLA, 1990
Golden Key National Honor Society, UCLA, 1988
Phi Beta Sigma National Honor Society, UCLA, 1987
Outstanding Students of America Award, UCLA, 1987

SOCIETY MEMBERSHIPS

American Society of Hematology
American Society of Clinical Oncology
Cancer Committee, Daniel Freeman Memorial Hospital
Medical Advisory Board, Prostate Cancer Research Institute

PUBLICATIONS

Lam, R., and R. Chlebowski. “Tamoxifen to Treat Premenopausal Women with Breast Cancer.” Cancer Investigation 18 (2000): 681-684.

Curti, Mario, Millie Leung, Richard Lam, Sohail Saeed, Priya Gulati, and Yutaka Niihara. “Successful Treatment of a Patient with Pure Red Cell Aplasia with Prednisone, Cyclosporine and Antithymocyte Globulin.” Medicine of the Americas 2, no. 2 (2001): 139-139.

Scholz, M., R. Lam, and B. Guess. “Anti-androgen Monotherapy for Prostate- Cancer.” PAACT 18, no. 2 (2002).

Scholz, M., R. Lam, S. Brosman, and B. Guess. “Calcitriol restores docetaxel anticancer activity in men with androgen independent prostate cancer who previously progressed on docetaxel. Proc West AUA (2003).

Cone, Lawrence A., Millie M. Leung, Richard G. Byrd, Gary M. Annunziata, Richard Y. Lam, and Brian K. Herman. “Multiple cerebral abscesses because of Listeria monocytogenes: three case reports and a literature review of supratentorial listerial brain abscess (es).” Surgical neurology 59, no. 4 (2003): 320-328.

Scholz, M., R. Lam, S. Brosman, and B. Guess. “Extent of disease on bone scan, baseline alkaline phosphatase, and 80% decline in PSA are the best indicators predicting long-term survival in men with androgen independent prostate cancer treated with ketoconazole.” Proc West AUA (2003).

Scholz, M., T. Trilling, S. Brosman, B. Guess, H. Johnson, and R. Lam. “PSA nadir greater than 0.1 on combined hormone blockade predicts the early development of androgen independent prostate cancer in men with PSA relapse after local therapy.” Proc West AUA (2003).

Guess, B. W., M. C. Scholz, S. B. Strum, R. Y. Lam, H. J. Johnson, and R. I. Jennrich. “Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study.” Prostate cancer and Prostatic Diseases 6, no. 4 (2003): 301-304.

Lam, R. Y., M. Scholz, B. Guess, J. Mahoney, H. Johnson, T. Trilling, and H. Goodman. “Oral bisphosphonates for the prevention of androgen deprivation therapy-associated bone loss-Preliminary findings.” In ASCO Annual Meeting Proceedings, vol. 22, no. 14_suppl, p. 4749. 2004.

Scholz, Mark, Robert Jennrich, Stephen Strum, Stanley Brosman, Henry Johnson, and Richard Lam. “Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone.” The Journal of Urology 173, no. 6 (2005): 1947-1952.

Scholz, M., R. Lam, B. Guess, and R. Blum. “When Should You Start Treatment with Ketoconazole?” PAACT 21, no. 4 (2005).

Scholz, M., R. Lam, S. Strum, H. Johnson, T. Trilling, and R. Jennrich. “Intermittent Use of Testosterone-Inactivating-Pharmaceuticals using Finasteride during Testosterone-Recovery Prolongs the Time-Off-Period.” Abstract. Multidisciplinary Prostate Cancer Symposium (2005): 153.

Lam, R., M. Scholz, B. Guess, and T. Trilling. “Oral Bisphosphonates Fail to Prevent Bone Loss from Androgen Deprivation Therapy in Men with Prostate Cancer.” ASCO Multidisciplinary Prostate Conference, 2006.

Scholz, Mark C., Robert I. Jennrich, Stephen B. Strum, Henry J. Johnson, Brad W. Guess, and Richard Y. Lam. “Intermittent use of testosterone inactivating pharmaceuticals using finasteride prolongs the time off period.” The Journal of Urology 175, no. 5 (2006): 1673-1678.

Guess, Brad W., Mark C. Scholz, and Richard Y. Lam. “Preventing and treating the side effects of testosterone inactivating pharmaceuticals in men with prostate cancer.” In Seminars in Preventive and Alternative Medicine, vol. 2, no. 2, (2006): 76-84.

Scholz, M. C., R. Lam, B. Guess, S. Strum, H. Johnson, and R. Jenrrich. “Ultrasensitive PSA nadir on testosterone inactivating pharmaceuticals accurately predicts early prostate cancer progression.” In ASCO Annual Meeting Proceedings, vol. 24, no. 18_suppl, p. 14531. 2006.

Porter, Michael P. “Outcomes of treatment vs observation of localized prostate cancer in elderly men.” Jama 297, no. 15 (2007): 1651-1653.

Scholz, M., Bahn, D., and Lam, R., “Active Surveillance with High Resolution Color-Doppler Transrectal Ultrasound Monitoring: Is it Foolproof?” PCRI Insights 10, no. 1 (2007).

Scholz, Mark, Richard Lam, Stephen Strum, Robert Jennrich, Henry Johnson, and Tom Trilling. “Prostate cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone inactivating pharmaceuticals.” Urology 70, no. 3 (2007): 506-510.

Scholz, M., R. Lam, S. Strum, and H. Johnson. “Active Surveillance after Induction with Testosterone Inactivating Pharmaceuticals (TIP): Ten Year Outcome.” Abstract. Active Surveillance Symposium 10 (2007).

Scholz, M., Lam, R., and Mendenhall, M. “My Doc Personalized Patient Information”, Novartis Oncology, DVD. USA: Novartis, 2009.

Lam, R., “High Dose Ketoconazole Plus Hydrocortisone (HDK+HC).” PAACT, Inc. Prostate Cancer Communication Newsletter 26, no 3 (2010).

Scholz, Mark C., Richard Y. Lam, Stephen B. Strum, Dean J. LaBarba, Lauren K. Becker, Patricia Chang, Nojan Farhoumand, and Robert I. Jennrich. “Primary intermittent androgen deprivation as initial therapy for men with newly diagnosed prostate cancer.” Clinical Genitourinary Cancer 9, no. 2 (2011): 89-94.

Lam, R., “Experience with sipuleucel-t (Sip-T) in a community oncology clinic: Initial 50 patients.” Abstract. ASCO-GU (2012).

Scholz, Mark C., Meg K. Groom, Andrew J. Kaddis, Stephen B. Strum, Robert I. Jennrich, Duke K. Bahn, Patricia J. Chang, Lauren K. Becker, and Richard Y. Lam. “Primary androgen deprivation (AD) followed by active surveillance (AS) for newly diagnosed prostate cancer (PC): a retrospective study.” The Prostate 73, no. 1 (2013): 83-88.

Scholz, M., R. Lam, J. Turner, and C.U. Felarca. “Y-90 resin in castrate-resistant prostate cancer with liver metastasis.” Abstract. ASCO Gastrointestinal Cancers Symposium (2016).

Scholz, M., S. Yep, C. Kelly, K.N. Chau, J. Turner, and R. Lam. “Phase I trial of sipuleucel-T combined with ipilimumab (SIPIPI) in progressive M-CRPC.” Abstract. ASCO (2016).

Scholz, M., R. Lam, and J. Turner. “Sir-Spheres (SS) for prostate cancer (PC) metastatic to liver.” Abstract. Genitourinary Cancers Symposium (2016).

CLINICAL TRIALS

212082PCR3001: An Open Label Study of Abiraterone Acetate in Subjects with Metastatic Castration-Resistant Prostate Cancer Who Have Progressed after Taxane-based Chemotherapy.

9785-CL-0401: A Multicenter, Single-arm, Open Label Treatment Protocol to Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy.

Addition of Bevacizumab to Taxanes Restores Anti-cancer Efficacy of Taxanes in Taxane-Refractory Prostate Cancer.

Androgen Replacement for Prostate Cancer Patients with Testicular Failure.

BMS184-043: A Randomized, Double-blind, Phase III Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects with Castration Resistant Prostate Cancer that Have Received Prior Treatment with Docetaxel.

BMS184-095: A Randomized, Double-blind, Phase III Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients with Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer.

COU-AA-301: A Phase III, Randomized, Double-blind, Placebo-controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy.

COU-AA-302: A Phase III, Randomized, Double-blind, Placebo-controlled study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Cancer.

CRPC2: A Multinational Phase III, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Oral MDV3100 in Patients with Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy.

GU 115/I6A-MC-CBBD: A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer.

Lack of Benefit of Local Therapy for Men with Preexisting AIPC.

OGX-011-11: A Randomized Phase III Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination with Custersin (OGX-011) in Men with Metastatic Castrate-Resistant Prostate Cancer.

OGX-011-12: A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination with Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men with Metastatic Castrate Resistant Prostate Cancer (AFFINITY).

ONC-MA-1004: A Prospective Observational Cohort Study of Patients with Castration-Resistant Prostate Cancer in the United States.

P10-3 PROCEED: A Registry of Sipuleucel-T Therapy in Men with Advanced Prostate Cancer.

P11-3: A Randomized, Open-label, Phase 2 Trial of Sipuleucel-T with Concurrent Versus Sequential Administration of Abiraterone Acetate plus Prednisone in Men with Metastatic Castrate Resistant Prostate Cancer (mCRPC).

P11-4 PRIME: Immune Monitoring Protocol in Men with Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T.

P12-1: A Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients with Castration-Resistant Prostate Cancer.

Prevention of Gynecomastia with an Aromatase Inhibitor Femara.

PROCEDE-1000: An Open Registry to Measure the Impact of Adding Genomic Testing (Prolaris®) on the Treatment Decision Following Biopsy in Newly Diagnosed Prostate Cancer Patients
Prognostic Significance of Negative Biopsy after 12 Months of Hormone Blockade.

SIPIPI 2013: Phase 1 Study of Sipuleucel-T and Ipilimumab in Combination for Advanced Prostate Cancer
Testosterone Replacement for Hypogonadal Men with Treated Prostate Cancer.
The Effect of Finesteride on Prolonging Time off in Patients on Intermittent Hormone Blockade
The Prevention of Bone Loss with Oral Bisphosphonates.

TOK-200-15: A Phase 3, Randomized, Open Label, Multicenter, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC).

XL184-306: A Phase III, Randomized, Double-blind, Controlled Trial of Cabzantinib (XL184) vs. Mitoxantrone Plus Prednisone in Men with Previously Treated Symptomatic Castration-resistant Prostate Cancer.